Partial Response to First-Line Crizotinib in an Elderly Male Patient with ROS1 Translocation-Positive Lung Cancer.

Case Rep Oncol 2016 Jan-Apr;9(1):158-63. Epub 2016 Mar 10.

Lungentumorzentrum Universität Göttingen and Göttingen Comprehensive Cancer Center (G-CCC), University Hospital Göttingen, Göttingen, Germany; Lungentumorzentrum Universität Göttingen and Göttingen Comprehensive Cancer Center (G-CCC), University Hospital Göttingen, Göttingen, Germany.

We report on a 90-year-old male patient with a ROS1-translocated adenocarcinoma of the lung who was treated with crizotinib as first-line therapy. After 11 months of treatment, we noticed complete metabolic response as measured by (18)F-FDG-PET/CT scan and a partial response according to RECIST criteria. This patient indicates that ROS1 translocations are not restricted to young age, female gender and low stage. Furthermore, this case illustrates exemplarily that crizotinib therapy is effective and manageable even as first-line treatment in elderly patients with comorbidities. Based on our findings, we recommend to include elderly patients with advanced pulmonary adenocarcinomas in molecular screening approaches for ROS1 translocations.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000444745DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821145PMC
April 2016
13 Reads

Publication Analysis

Top Keywords

elderly patients
8
ros1 translocations
8
male patient
8
partial response
8
age female
4
young age
4
restricted young
4
female gender
4
gender low
4
case illustrates
4
stage case
4
low stage
4
translocations restricted
4
metabolic response
4
scan partial
4
18f-fdg-pet/ct scan
4
measured 18f-fdg-pet/ct
4
response recist
4
recist criteria
4
illustrates exemplarily
4

Similar Publications